RxDoctor Payments Data

Vimal Sarup, MD

Ophthalmology · Deerfield Beach, FLNPI 1073837787

Payments from drug & device makers

$4,028in general payments, 2019–2025

Across 43 payments — averaging $93.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$2K
  • Astellas Pharma US Inc$438
  • Apellis Pharmaceuticals, Inc.$412
  • Mallinckrodt Hospital Products Inc.$393
  • AbbVie$377
  • Genentech USA, Inc.$244
  • plus $415 from 6 others
$1,569in research payments, 2019–2025

Across 13 payments — averaging $120.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim International GmbH$2K

What the payments were for

  • Travel & lodging$1,43236%
  • Food & beverage$2,59764%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,028 in reported general payments places this provider in the 65th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$476,076
Medicare patients
307
Services billed
4,416

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketorolac Tromethamine549$22,882
Prednisolone Acetate230$11,814
ProlensaBromfenac Sodium22$8,663
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$6,606
LumiganBimatoprost15$6,503
CombiganBrimonidine Tartrate/Timolol14$4,480
Bromfenac Sodium16$4,421
Latanoprost445$4,285
MoxifloxacinMoxifloxacin Hcl86$2,989
Brimonidine Tartrate273$2,984
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat120$1,549
Acetazolamide23$992
Atropine Sulfate18$730
Dorzolamide Hcl36$612
Timolol Maleate53$594

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$377$10,98329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Deerfield Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →